Cost-effectiveness of Adding an Agent That Improves Immune Responses to Initial Antiretroviral Therapy (ART) in HIV-Infected Patients: Guidance for Drug Development

REFERENCES

• Chêne G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet. 2003;362(9385):679–686. PMID:12957089.
   PubMed Web of Science ®Google Scholar
• Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active anti-retroviral therapy. Ann Intern Med. 2000;133(6):401–410. PMID:10975957.
   PubMed Web of Science ®Google Scholar
• Zoufaly A, ander Heiden M, Kollan C, et al. Clinical out-come of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis. 2011;203(3):364–371. PMID:21208929.
   PubMed Web of Science ®Google Scholar
• Abrams D', Levy Y, Losso MH', et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361(16): 1548–1559. PMID:19828532.
   Web of Science ®Google Scholar
• Wilkin TJ, Lalama C, Tenorio A, et al. Maraviroc (MVC) intensification for supoptimal CD4+ response despite sustained virologic supression: ACTG 5256. In: Program and abstracts of the 17th Conference of Retroviruses and Opportunistic Infections (CR01); February 16–19, 2010; San Francisco, CA, USA. Abstract 285.
   Google Scholar
• Hunt P, Shulman N, Hayes T, et al. Immunomodulatory effects of MVC intensification in HIV-infected individuals with incomplete CD4+ T cell recovery during suppressive ART. In: Program and abstracts of the 18th Conference on Retroviruses and Opportunistic Infections (CR01); February 27-March 2, 2011; Boston, MA, USA. Abstract 153 LB.
   Google Scholar
• ClinicalTrials.gov. Maraviroc (CCR5) antagonism to decrease the incidence of the Immune Reconstitu-tion Inflammatory Syndrome in HIV-infected patients (CADIRIS). US National Institutes of Health. http://clini-caltrials.gov/ct2/show/results/NCT00988780. Accessed March 12, 2011.
   Google Scholar
• Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis. 2010;201(6): 803–813. PMID:20151839.
   PubMed Web of Science ®Google Scholar
• Sierra-Madero J, Di Perri G, Wood R, et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/ lamivudine: 96-week results from the MERIT study. HIV Clin Trials. 2010;11(3):125–132. PMID:20736149.
   PubMed Web of Science ®Google Scholar
• Schackman BR, Gebo KA, Walensky RP, et al. The life-time cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990–997. PMID:17063130.
   PubMed Web of Science ®Google Scholar
• Schackman BR, Scott CA, Sax PE, et al. Potential risks and benefits of HIV treatment simplification: a simula-tion model of a proposed clinical trial. Clin Infect Dis. 2007;45(8)1 062–1070. PMID:17879926.
   Web of Science ®Google Scholar
• Schackman BR, Scott CA, Walensky RP, Losina E, Freed-berg KA, Sax PE. The cost-effectiveness of HLA-B"5701 genetic screening to guide initial antiretroviral therapy for HIV. AIDS. 2008;22(15):2025–2033. PMID:18784465.
   Web of Science ®Google Scholar
• Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
   Google Scholar
• Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46(4):349–356. PM ID:18362813.
   PubMed Web of Science ®Google Scholar
• Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163(14): 1637–1641. PMID:12885677.
   Google Scholar
• Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8(2):165–178. PMID:20528406.
   PubMedGoogle Scholar
• Schackman BR, Gold HT, Stone PW, Neumann PJ. How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions? Pharmacoeco-nomics. 2004;22(5):293–300. PMID:15061679.
   PubMed Web of Science ®Google Scholar
• Kim JJ, Ortendahl J, Goldie SJ. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States. Ann Intern Med. 2009;151(8):538–545. PMID:19841455.
   PubMed Web of Science ®Google Scholar
• Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007;45\(Suppl 4):5248–254. PMID:18190295.
   Google Scholar
• Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–954. PMID:9182471.
   PubMed Web of Science ®Google Scholar
• Multicenter AIDS Cohort Study (MACS). Public Dataset: Release PO4 [database on the Internet]. Springfield, VA: National Technical Information Service; 1995.
   Google Scholar
• Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med. 2001 344 (11):824–831 . PMID:11248160.
   PubMed Web of Science ®Google Scholar
• Freedberg KA, Scharfstein JA, Seage GR 3rd, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279(2)1 30–136. PMID:9440663.
   Web of Science ®Google Scholar
• Samet JH, Freedberg KA, Savetsky JB, Sullivan LM, Stein MD. Understanding delay to medical care for HIV infec-tion: the long-term non-presenter. AIDS. 2001;15(1):77–85. PMID:11192871.
   PubMed Web of Science ®Google Scholar
• Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. January 10, 2011. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed March 22, 2011.
   Google Scholar
• Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adoles-cents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infec-tious Diseases Society of America. MMWR Recomm Rep. 2009;58( RR-4):1-207. PMID:19357635.
   Google Scholar
• Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in anti-retroviral-naive patients: virologic, immunologic, and mor-phologic changes-a 96-week analysis. J Acquir Immune Defic Syndr 2006;43(5):535–540. PMID:17057609.
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354(3):251–260. PMID:16421366.
   PubMed Web of Science ®Google Scholar
• Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and effi-cacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase 11 randomised controlled trial. Lancet. 2007;369(9569)1261-9. PMID:17434401.
   Web of Science ®Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. Atazana-vir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS. 2005;19(7):685–694. PMID:15821394.
   PubMed Web of Science ®Google Scholar
• Johnson MA, Gathe JC Jr, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006;43(2):153–160. PMID:16951643.
   PubMed Web of Science ®Google Scholar
• Lalezari J, Goodrich J, DeJesus E, et al, eds. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 21D/3 study in the US and Canada [Abs: 104bLB]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; February 25–28, 2007; Los Angeles, CA.
   Google Scholar
• Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized back-ground regimen only 1 and 2 clinical trials. JAcquirlmmune Defic Syndr 2005;40(4):404–412. PMID:16280694.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for pre-viously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14): 1429–1441. PMID:18832244.
   Web of Science ®Google Scholar
• Arias E. United States Life Tables, 2004: National Vital Sta-tistics Reports. Centers for Disease Control and Prevention; 2007.
   Google Scholar
• Texas Department of State Health Services. Texas vital sta-tistics: life tables. 2005. http://www.dshs.state.tx.us/chs/vstat/annrpts.shtm. Accessed March 22,2011.
   Google Scholar
• Losina E, Schackman BR, Sadownik SN, et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of anti-retroviral therapy. Clin Infect Dis. 2009;49(10): 1570–1578. PMID:19845472.
   Web of Science ®Google Scholar
• Centers for Medicare and Medicaid Services. Medicare Physician Fee Schedule. http://www.cms.hhs.gov/physi-cianfeesched/downloads/RVUO8D.zip. Accessed October 3, 2011.
   Google Scholar
• Red Book. Montvale, NJ: Thomson Reuters; 2009.
   Google Scholar
• Gebo KA, Moore RD, Fleishman JA. The HIV Research Network: a unique opportunity for real time clinical utili-zation analysis in HIV. Hopkins HIV Rep. 2003;15(6):5–6. PMID:14974424.
   PubMedGoogle Scholar
• University HealthSystems Consortium. CDP online report. 2008. www.uhc.edu. Accessed July 27,2011.
   Google Scholar
• Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis. 2010;50(11): 1512–1520. PM I D:20415573.
   Web of Science ®Google Scholar
• Vital signs: HIV testing and diagnosis among adults—United States, 2001–2009. MMWR Morb Mortal Wkly Rep. 2010;59(47):1550–1555. PMID:21124295.
   PubMedGoogle Scholar